 |
 
|
|
Best Practice works with pharmaceutical companies to design research projects and host conferences related to specific issues related to medical and public policy. These conferences and research projects do not focus on regulatory issues; rather they are focused on specific policy issues related to a single drug or class of drugs. Each of these projects is typically funded by an unrestricted educational grant from a single company. Best Practice takes full responsibility for planning the projects and convenes groups of experts to design a research plan or a conference that gathers together representatives from broad groups, including therapeutic experts, managed care, managed behavioral health, public policy, economics, and statistics. Issues covered might include reimbursement, restricted formularies, generic substitution, or defining new therapeutic indications. Most conferences and research projects result in papers to be submitted to peer-reviewed journals.
Some Targeted Policy-related Conferences convened by Best Practice include:
2003 Conference
“Public Health Implications of Smokeless Tobacco Use as a Harm Reduction Strategy”
Paper accepted for publication and currently in press in the American Journal of Public Health
2002 Conference
“The Case for Physician Choice: Implications for Restricted Formularies”
Published in 2003 as a Supplement to the Journal of Clinical Psychiatry. Links to each article:
Jaffe, AB, Levine, J. (2003).
Efficacy and Effectiveness of First- and Second-generation Antipsychotics in Schizophrenia. J Clin Psychiatry. 64 Suppl 17:3-6.
Tamminga, CA (2003).
Similarities and Differences Among Antipsychotics. J Clin Psychiatry, 64 Suppl 17:7-10.
Goodwin, FK (2003).
Impact of Formularies on Clinical Innovation. J Clin Psychiatry, 64 Suppl 17:11-4.
Lichtenberg, FR (2003).
The Economic and Human Impact of New Drugs. J Clin Psychiatry, 64 Suppl 17:15-8.
Soumerai, S (2003).
Unintended Outcomes of Medicaid Drug Cost-containment Policies on the Chronically Mentally Ill. J Clin Psychiatry, 64 Suppl 17:19-22.
Horn, SD (2003).
Limiting Access to Psychiatric Services Can Increase Total Health Care Costs. J Clin Psychiatry, 64 Suppl 17:23-8.
de Lissovoy, G
Weighing the Evidence: Trends in Managed Care Formulary Decision Making. J Clin Psychiatry, 64 Suppl 17:29-32.
Moore, MC (2003).
Commentary: Purchasing Community Perspective. J Clin Psychiatry, 64 Suppl 17:33-4.
Goldman, W (2003).
Commentary: Health Care Organization Perspective. J Clin Psychiatry, 64 Suppl 17:35-6.
Parks, JJ (2003).
Commentary: Government Perspective. J Clin Psychiatry, 64 Suppl 17:37-8.
Fitzpatrick, MJ (2003).
Commentary: Advocacy Perspective. J Clin Psychiatry, 64 Suppl 17:39-40.
|
|
|
|
